Marketing-authorisation holder
Sanofi Vaccines Canada Ltd.
68 medicines in 2 countries, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder
68 medicines in 2 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 68
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ACT-HIB10 mcg / 0.5 ml + 30 mcg / 0.5 ml · Kit, Powder For Solution | Haemophilus influenzae type b-prp, Tetanus protein | Canada | Marketed | 1992 |
| Adacel0.5ml · Injection | Tetanus toxoid, reduced diphtheria toxoid, Acellular pertussis vaccine, adsorbed | United States | Marketed | 2005 |
| ADACEL2 lf / 0.5 ml + 5 mcg / 0.5 ml + 5 mcg / 0.5 ml + 3 mcg / 0.5 ml + 2.5 mcg / 0.5 ml + 5 lf / 0.5 ml · Suspension | Diphtheria toxoid, Filamentous haemagglutinin, Fimbriae types and, Pertactin, Pertussis toxoid, Tetanus toxoid | Canada | Marketed | 1999 |
| ADACEL-POLIO2 lf / 0.5 ml + 5 mcg / 0.5 ml + 5 mcg / 0.5 ml + 3 mcg / 0.5 ml + 2.5 mcg / 0.5 ml + 29 unit / 0.5 ml + 7 unit / 0.5 ml + 26 unit / 0.5 ml + 5 lf / 0.5 ml · Suspension | Diphtheria toxoid, Filamentous haemagglutinin, Fimbriae types and, Pertactin, Pertussis toxoid, Poliovirus type mahoney, Poliovirus type mef1, Poliovirus type saukett, Tetanus toxoid | Canada | Marketed | 2011 |
| AVAXIM160 unit / 0.5 ml · Suspension | Hepatitis a virus, inactivated | Canada | Marketed | 1999 |
| BEYFORTUS50 mg / 0.5 ml · Solution | Nirsevimab | Canada | Marketed | 2024 |
| BEYFORTUS100 mg / 1 ml · Solution | Nirsevimab | Canada | Marketed | 2024 |
| Daptacel0.5ml · Injection | Diphtheria tetanus toxoids acellular pertussis vaccine adsorbed | United States | Marketed | 2002 |
| FLUZONE15 mcg / 0.5 ml + 15 mcg / 0.5 ml + 15 mcg / 0.5 ml · Suspension | Haemagglutinin-strain a, Haemagglutinin-strain b | Canada | Marketed | 2014 |
| FLUZONE15 mcg / 0.5 ml + 15 mcg / 0.5 ml + 15 mcg / 0.5 ml · Suspension | Haemagglutinin-strain a, Haemagglutinin-strain b | Canada | Marketed | 2014 |
| FLUZONE HIGH-DOSE60 mcg / 0.5 ml + 60 mcg / 0.5 ml + 60 mcg / 0.5 ml · Suspension | Haemagglutinin-strain a, Haemagglutinin-strain b | Canada | Marketed | 2016 |
| FLUZONE HIGH-DOSE QUADRIVALENT60 mcg / 0.7 ml + 60 mcg / 0.7 ml + 60 mcg / 0.7 ml + 60 mcg / 0.7 ml · Suspension | Haemagglutinin-strain a, Haemagglutinin-strain b | Canada | Not marketed | 2021 |
| FLUZONE QUADRIVALENT30 mcg / ml + 30 mcg / ml + 30 mcg / ml + 30 mcg / ml · Suspension | Haemagglutinin-strain a, Haemagglutinin-strain b | Canada | Not marketed | 2015 |
| FLUZONE QUADRIVALENT15 mcg / 0.5 ml + 15 mcg / 0.5 ml + 15 mcg / 0.5 ml + 15 mcg / 0.5 ml · Suspension | Haemagglutinin-strain a, Haemagglutinin-strain b | Canada | Not marketed | 2014 |
| IMOVAX POLIO29 unit / 0.5 ml + 7 unit / 0.5 ml + 26 unit / 0.5 ml · Solution | Poliovirus type mahoney, Poliovirus type mef1, Poliovirus type saukett | Canada | Marketed | 2007 |
| IMOVAX RABIES2.5 unit / vial · Powder For Suspension | Inactivated rabies virus | Canada | Marketed | 1999 |
| MENQUADFI10 mcg / 0.5 ml + 10 mcg / 0.5 ml + 10 mcg / 0.5 ml + 10 mcg / 0.5 ml + 55 mcg / 0.5 ml · Solution | Meningococcal group a polysaccharide-tetanus toxoid conjugate, Meningococcal group c polysaccharide-tetanus toxoid conjugate, Meningococcal group w polysaccharide-tetanus toxoid conjugate, Meningococcal group y polysaccharide-tetanus toxoid conjugate, Tetanus toxoid | Canada | Marketed | 2025 |
| NUVAXOVID5 mcg / 0.5 ml · Suspension | Sars-cov-2 recombinant spike protein | Canada | Not marketed | 2023 |
| NUVAXOVID5 mcg / 0.5 ml · Suspension | Sars-cov-2 recombinant spike protein | Canada | Marketed | 2026 |
| PANENZA15 mcg / 0.5 ml · Suspension | Haemagglutinin-strain a | Canada | Authorised | |
| Pentacel0.5ml · Injection | Diphtheria, Tetanus toxoids, Acellular pertussis adsorbed, inactivated poliovirus, Haemophilus b conjugate vaccine | United States | Marketed | 2008 |
| PENTACEL15 lf / 0.5 ml + 20 mcg / 0.5 ml + 5 mcg / 0.5 ml + 10 mcg / 0.5 ml + 3 mcg / 0.5 ml + 20 mcg / 0.5 ml + 29 unit / 0.5 ml + 7 unit / 0.5 ml + 26 unit / 0.5 ml + 30 mcg / 0.5 ml + 5 lf / 0.5 ml · Suspension | Diphtheria toxoid, Filamentous haemagglutinin, Fimbriae, Haemophilus influenzae type b-prp, Pertactin, Pertussis toxoid, Poliovirus type mahoney, Poliovirus type mef1, Poliovirus type saukett, Tetanus protein, Tetanus toxoid | Canada | Marketed | 2024 |
| Poliovax0.5ml · Injection | Inactivated poliovirus vaccine | United States | Not marketed | 2000 |
| Poliovax0.5ml · Injection | Inactivated poliovirus vaccine | United States | Not marketed | 2000 |
| Quadracel0.5ml · Injection | Diphtheria, Tetanus toxoids, Acellular pertussis adsorbed, Inactivated poliovirus vaccine | United States | Not marketed | 2015 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 54 | 25 | 29 | CompaniesAll medicines |
| United States | 14 | 10 | 4 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.